Already have an account? Sign in.
AppLovin Climbs as Citi Says Tumble is a Buying Opportunity
SEC is probing AppLovin’s data. Stock fell, but Citi analysts call the drop "extreme" and urge investors to buy the shares now.
SEC is probing AppLovin’s data. Stock fell, but Citi analysts call the drop "extreme" and urge investors to buy the shares now.
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
Bernstein says Fiserv’s appointment of Takis Georgakopoulos as CEO has a “bad look,” coming just weeks after Investor Day while the stock is at 10-year lows.
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.